PTJ
IOVA icon

Paul Tudor Jones’s Iovance Biotherapeutics IOVA Stock Holding History

Paul Tudor Jones’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Buy
+50,000
New +$190K ﹤0.01% 3312

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Paul Tudor Jones's IOVA Position: Q2 2026 in Review

Paul Tudor Jones increased its Iovance Biotherapeutics (IOVA) stake by 36% in Q2 2026, buying an estimated $296K and bringing the position to 293,989 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2267.

Paul Tudor Jones first reported a position in IOVA in Q1 2015 and has held it in 21 quarters since. The position peaked at $4.75M in Q1 2021. 289 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Paul Tudor Jones held 293,989 shares of Iovance Biotherapeutics worth $1.22M as of Q2 2026.
  • Paul Tudor Jones bought 77,985 Iovance Biotherapeutics shares in Q2 2026, an estimated $296K.
  • Iovance Biotherapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2267 holding.
  • Paul Tudor Jones first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 21 quarters since.
  • Paul Tudor Jones's Iovance Biotherapeutics position peaked at $4.75M in Q1 2021.
  • 289 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.